I used to be of the opinion that the study be in the high hundreds. Given the type of study ( and the overwhelming results ) I’m thinking 200-300. The smaller the difference in overall performance of the comparable devices the more you would need. Wayne seemed to emphasise something to this effect in the AGM presentation
Clinical trials, page-22
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.14 |
Change
0.140(1.08%) |
Mkt cap ! $277.7M | |||
| Open | High | Low | Value | Volume |
| $13.20 | $13.50 | $13.14 | $559.5K | 42.05K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1180 | $13.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.35 | 500 | 1 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |